This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride an antidepressant which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets.

This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride an antidepressant which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets.

This invention provides O- alpha -acyloxyalkyl ethers of the venlafaxine metabolite 4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol represented by Formula (I); wherein the configuration at the steriogenic center (*) may be R S or RS (the racemate); R1 is selected from C1-C6 alkyl C1-C6 alkoxy C3-C6 cycloalkyl or the moiety: (a); R2 is selected from H or C1-C6 alkyl; or R1 and R2 may be concatenated such that (i) form a moiety having formula (b); R3 is selected from H or C1-C6 alkyl; and ...

This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride an antidepressant which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets.

The present invention provides enantiomers of N-Desmethyl venlafaxine as well as their use in pharmaceutical compositions and medically useful treatments particularly including central nervous system uses.

This invention provides pharmaceutically active enantiomers of the venlafaxine metabolite O-Desmethyl venlafaxine R(-)-4-[2-(Dimethylamino-1-(1-hydroxycyclo-hexyl)ethyl]phenol or R(-)1-[2-(dimethylamino)-1-(4-hydroxyphenyl)-ethyl]cyclo-hexanol and S(+)-1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]-cyclohexanol or S(+)-4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol or one or more pharmaceutically acceptable salts or salt hydrates thereof as well as pharmaceutical compositions utilizing...

This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride and antidepressant which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. In its primary aspect this invention provides an improved core of the extended release spheroids comprised of venlaf...

An encapsulated a 24 hour extended release formulation of venlafaxine hydrochloride comprising a hard gelatin capsule containing a therapeutically effective amount of spheroids comprised of venlafaxine hydrochloride microcrystalline cellulose and hydroxypropyl methylcellulose coated with ethyl cellulose and hydroxypropylmethylcellulose. The formulatyion provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day.

This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride an antidepressant which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets.

This invention provides a method of treating obesity generalized anxiety disorder post-traumatic stress disorder late luteal phase disphoric disorder (premenstrual syndrome) attention deficit disorder with and without hyperactivity Gilles de la Tourette syndrome bulimia nervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethylamine of the following structural formula: in which A is a moiety of the formula where the dotted lin...